Skip Navigation


European Heart Journal Advance Access originally published online on July 10, 2008
European Heart Journal 2008 29(15):1795-1797; doi:10.1093/eurheartj/ehn281
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/15/1795    most recent
ehn281v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Abbate, A.
Right arrow Articles by Biondi-Zoccai, G. G.L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abbate, A.
Right arrow Articles by Biondi-Zoccai, G. G.L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

No-reflow: the next challenge in treatment of ST-elevation acute myocardial infarction

Antonio Abbate1,*, Michael C. Kontos1 and Giuseppe G.L. Biondi-Zoccai2

1 VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA 23298-0281, USA
2 Division of Cardiology, University of Turin, Turin, Italy

* Corresponding author. Tel: +1 804 2702946, Fax +1 360 3231204, Email: aabbate@mcvh-vcu.com

This editorial refers to ‘Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention’{dagger} by G. Niccoli et al., on page 1843

Footnotes

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

The first 10% of the full text of this article appears below.

Coronary revascularization is not synonymous with myocardial reperfusion. DeWood et al.1 almost three decades ago showed that ~90% of patients with transmural myocardial infarction had total coronary occlusion at angiography associated with acute thrombosis. This and other studies have paved the way for the use of fibrinolytics in the treatment of transmural or ST-segment elevation myocardial infarction (STEMI). Despite the clear benefits observed with fibrinolysis, a significant proportion of patients failed to achieve adequate reperfusion as witnessed by persistence of total coronary occlusion, slow epicardial flow at angiography, or failure of regression . . . [Full Text of this Article]

Pathophysiology of no-reflow

Clinical perspective


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention
Giampaolo Niccoli, Simona Giubilato, Eleonora Russo, Cristina Spaziani, Andrea Leo, Italo Porto, Antonio M. Leone, Francesco Burzotta, Silvia Riondino, Fabio Pulcinelli, Luigi M. Biasucci, and Filippo Crea
EHJ 2008 29: 1843-1850. [Abstract] [FREE Full Text]